ePrints

Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia

Lookup NU author(s): Dr Tryfonia Mainou-Fowler, Dr Gordon Strathdee

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Chronic lymphocytic leukemia (CLL) exhibits a highly variable clinical course. Altered DNA methylation of genes has shown promise as a source of novel prognostic makers in a number of cancers. Here we have studied the potential utility of a panel of methylation markers (CD38, HOXA4 and BTG4) in 118 CLL patients. Each of the three loci assessed exhibited frequent methylation, as determined by COBRA analysis and individually correlated with either good (CD38, BTG4 methylation) or poor (HOXA4 methylation) prognosis. Using a combined approach to produce an overall methylation score, we found that methylation score was significantly associated with time to first treatment in CLL patients. Multivariate Cox regression analysis revealed that methylation score was the strongest predictor of time to first treatment and was independent of IGHV gene mutational status and CD38 expression. This study provides proof of principle that a panel of methylation markers can be used for additional risk stratification of CLL patients.

Publication metadata

Author(s): Irving L, Mainou-Fowler T, Parker A, Ibbotson RE, Oscier DG, Strathdee G

Publication type: Article

Publication status: Published

Journal: Epigenetics

Year: 2011

Volume: 6

Issue: 3

Pages: 300-306

Print publication date: 01/03/2011

ISSN (print): 1559-2294

ISSN (electronic): 1559-2308

Publisher: Landes Bioscience

URL: http://dx.doi.org/10.4161/epi.6.3.14038

DOI: 10.4161/epi.6.3.14038

Altmetrics

Share